Imvax has secured $29 million in funding to advance IGV-001, an autologous biologic-device combination therapy for newly diagnosed glioblastoma, bringing total fundraising to $86 million over 21 months.
Imvax is developing Goldspire™, a personalized immunotherapy platform, to treat glioblastoma (GBM) by leveraging the complete antigenic profile of a patient's tumor.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.